$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023042072 Filed on May 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$37.00K	$22.00K	$0.00
YoY Change
Cost Of Revenue	$23.00K	$31.00K
YoY Change
Gross Profit	$14.00K	-$9.000K
YoY Change
Gross Profit Margin	37.84%	-40.91%
Selling, General & Admin	$4.409M	$3.576M	$2.367M
YoY Change	46.87%	3.03%	-47.86%
% of Gross Profit	31492.86%
Research & Development	$490.0K	$541.0K	$584.0K
YoY Change	-66.73%	-50.64%	-54.2%
% of Gross Profit	3500.0%
Depreciation & Amortization	$192.0K	$128.0M	$143.0K
YoY Change	182.35%	119526.17%	64.37%
% of Gross Profit	1371.43%
Operating Expenses	$4.899M	$4.117M	$2.951M
YoY Change	9.47%	-9.85%	-49.25%
Operating Profit	-$4.885M	-$4.126M
YoY Change	9.16%	-9.66%
Interest Expense	$2.508M	$2.017M	-$150.0K
YoY Change	125300.0%	-67333.33%	4900.0%
% of Operating Profit
Other Income/Expense, Net	-$9.634M	$1.826M	$949.0K
YoY Change	481600.0%	-60966.67%	-15916.67%
Pretax Income	-$14.52M	-$2.300M	-$2.152M
YoY Change	224.3%	-49.67%	-60.04%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$14.52M	-$2.300M	-$2.184M
YoY Change	224.3%	-49.67%	-59.45%
Net Earnings / Revenue	-39240.54%	-10454.55%
Basic Earnings Per Share	-$2.720K	-$4.88
Diluted Earnings Per Share	-$18.02	-$0.08	-$0.11
COMMON SHARES
Basic Shares Outstanding	50.71M shares	43.69M shares	20.24M shares
Diluted Shares Outstanding	811.0K shares	29.70M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.00K	$2.138M	$821.0K
YoY Change	-96.34%	-14.92%	-86.61%
Cash & Equivalents	$36.00K	$2.138M	$821.0K
Short-Term Investments
Other Short-Term Assets	$36.00K	$97.00K	$63.00K
YoY Change	-94.73%	-87.47%	-90.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$792.0K	$2.861M	$1.411M
YoY Change	-52.49%	-12.96%	-79.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.366M	$2.528M	$1.409M
YoY Change	116.67%	-17.63%	57.43%
Goodwill	$652.0K	$652.0K
YoY Change
Intangibles	$1.688M	$1.744M	$1.598M
YoY Change			-9.26%
Long-Term Investments
YoY Change
Other Assets	$33.00K	$213.0K	$180.0K
YoY Change	-91.81%	-47.01%	0.56%
Total Long-Term Assets	$11.36M	$15.11M	$5.179M
YoY Change	114.2%	191.3%	82.68%
TOTAL ASSETS
Total Short-Term Assets	$792.0K	$2.861M	$1.411M
Total Long-Term Assets	$11.36M	$15.11M	$5.179M
Total Assets	$12.15M	$17.97M	$6.590M
YoY Change	74.33%	112.06%	-31.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.822M	$1.146M	$865.0K
YoY Change	116.9%	247.27%	141.62%
Accrued Expenses	$408.0K	$230.0K	$621.0K
YoY Change	251.72%	-61.47%	108.39%
Deferred Revenue
YoY Change
Short-Term Debt	$1.800M	$4.710M	$1.662M
YoY Change	22400.0%	58775.0%	20675.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.235M	$9.016M	$4.694M
YoY Change	201.46%	864.28%	606.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$355.0K	$1.208M	$1.366M
YoY Change	-80.44%	-33.41%
Total Long-Term Liabilities	$355.0K	$1.208M	$1.366M
YoY Change	-80.44%	-33.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.235M	$9.016M	$4.694M
Total Long-Term Liabilities	$355.0K	$1.208M	$1.366M
Total Liabilities	$7.590M	$10.22M	$6.060M
YoY Change	80.07%	271.92%	812.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.8M	-$90.31M	-$88.01M
YoY Change	26.7%		19.43%
Common Stock	$6.000K	$4.000K	$2.000K
YoY Change	500.0%		100.0%
Preferred Stock	$700.0K	$4.350M
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.557M	$7.744M	$530.0K
YoY Change
Total Liabilities & Shareholders Equity	$12.15M	$17.97M	$6.590M
YoY Change	74.33%	112.06%	-31.72%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$14.52M	-$2.300M	-$2.184M
YoY Change	224.3%	-49.67%	-59.45%
Depreciation, Depletion And Amortization	$192.0K	$128.0M	$143.0K
YoY Change	182.35%	119526.17%	64.37%
Cash From Operating Activities	-$3.658M	-$4.728M	-$3.091M
YoY Change	52.99%	33.11%	-6.36%
INVESTING ACTIVITIES
Capital Expenditures	$267.0K	$435.0K	$473.0K
YoY Change	-205.12%	-769.23%	-275.19%
Acquisitions
YoY Change
Other Investing Activities	$6.000K	-$645.0K
YoY Change
Cash From Investing Activities	-$271.0K	-$1.080M	-$473.0K
YoY Change	6.69%	1561.54%	75.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.824M	$7.125M	4.043M
YoY Change	63.44%
NET CHANGE
Cash From Operating Activities	-3.658M	-$4.728M	-3.091M
Cash From Investing Activities	-271.0K	-$1.080M	-473.0K
Cash From Financing Activities	1.824M	$7.125M	4.043M
Net Change In Cash	-2.105M	$1.317M	479.0K
YoY Change	37.67%		-113.41%
FREE CASH FLOW
Cash From Operating Activities	-$3.658M	-$4.728M	-$3.091M
Capital Expenditures	$267.0K	$435.0K	$473.0K
Free Cash Flow	-$3.925M	-$5.163M	-$3.564M
YoY Change	83.67%	48.06%	17.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q4	us-gaap	Cash Cash	821000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	723000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2861000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1411000	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	333-232426
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Crown Electrokinetics Corp.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5423944
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1110 NE Circle Blvd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Corvallis
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	OR
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	97330
CY2023Q1	dei	City Area Code CityAreaCode	(800)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	674-3612
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50713135	shares
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	CRKN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	us-gaap	Cash Cash	2138000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2528000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1744000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1598000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1709000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1842000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	652000	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	8261000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	150000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	213000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	180000	usd
CY2023Q1	us-gaap	Assets Assets	17968000	usd
CY2022Q4	us-gaap	Assets Assets	6590000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1146000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	230000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	598000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	574000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2332000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2023Q1	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	3191000	usd
CY2022Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	1654000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1519000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9016000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4694000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1208000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1366000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	10224000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6060000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43686523	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20243509	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	98051000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88533000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90311000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88005000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7744000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17968000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6590000	usd
CY2023Q1	us-gaap	Revenues Revenues	22000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	31000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-9000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	541000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1096000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3576000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3471000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4117000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	4567000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4126000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4567000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2017000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-504000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2023Q1	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	5606000	usd
CY2023Q1	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-117000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	1206000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1826000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2300000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4570000	usd
CY2023Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	-6000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2416000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4570000	usd
CY2023Q1	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-0.08
CY2022Q1	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-0.29
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29695083	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15856316	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023Q1	crkn	Exercise Of Common Stock Warrants ExerciseOfCommonStockWarrants	2062000	usd
CY2023Q1	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes1 IssuanceOfCommonStockInConnectionWithConversionOfNotes1	516000	usd
CY2023Q1	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	2107000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4350000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	298000	usd
CY2023Q1	crkn	Stockbased Compensation StockbasedCompensation	181000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2300000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7744000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
CY2022Q1	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
CY2022Q1	crkn	Stockbased Compensation StockbasedCompensation	1083000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4570000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	5724000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2300000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4570000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	181000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1083000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	107000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-504000	usd
CY2023Q1	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability	5606000	usd
CY2023Q1	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-117000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1635000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	374000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	133000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	118000	usd
CY2023Q1	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	64000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	1206000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	87000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	125000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-32000	usd
CY2023Q1	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest	-920000	usd
CY2022Q1	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest	-208000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-134000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-15000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4728000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3552000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	645000	usd
CY2023Q1	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	435000	usd
CY2022Q1	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	58000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1080000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2062000	usd
CY2023Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2198000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	91000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	970000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	14000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7125000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1317000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3617000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2138000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2513000	usd
CY2023Q1	crkn	Issuance Of Series E Preferred Stock In Connection With Loc IssuanceOfSeriesEPreferredStockInConnectionWithLOC	4350000	usd
CY2023Q1	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes	516000	usd
CY2022Q1	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable	223000	usd
CY2023Q1	crkn	Commitment To Issue Shares Of Common Stock In Connection With March Waiver Agreement CommitmentToIssueSharesOfCommonStockInConnectionWithMarchWaiverAgreement	298000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2023Q1	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	156000	usd
CY2022Q1	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	4000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	8000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
CY2022Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1.3
CY2023Q1	crkn	Accumulated Deficit AccumulatedDeficit	90300000	usd
CY2023Q1	crkn	Working Capital WorkingCapital	6150000	usd
CY2023Q1	crkn	Net Loss NetLoss	2300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	4600000	usd
CY2023Q1	us-gaap	Debt Instrument Sinking Fund Payment DebtInstrumentSinkingFundPayment	10000000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	100000000	usd
CY2023Q1	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2022Q4	crkn	Placement Shares Amount PlacementSharesAmount	3500000	usd
CY2022Q4	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2023Q1	crkn	Net Proceeds On Sale Of Common Stock NetProceedsOnSaleOfCommonStock	12700000	shares
CY2023Q1	us-gaap	Payments For Commissions PaymentsForCommissions	2100000	usd
CY2023Q1	crkn	Share Based Compensation Arrangement By Share Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	0.173
CY2023Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-04-03
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000	usd
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	5000	shares
CY2023Q1	crkn	Warrant Purchase Shares WarrantPurchaseShares	45000	shares
CY2023Q1	crkn	Adjustment Warrant Share AdjustmentWarrantShare	1000	shares
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2060000.00	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6555095	shares
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of its business combination, senior secured convertible notes and warrants, and equity based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected
CY2023Q1	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted the new revenue standard, ASC 606, on March 31, 2019 using the full retrospective approach. The adoption did not have an effect on 2021 or 2020 revenue recognition or a cumulative effect on opening equity, as the timing and measurement of revenue recognition is materially the same as under ASC 605. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Step 1: Identify the contract with the customer</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Step 2: Identify the performance obligations in the contract</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Step 3: Determine the transaction price</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s performance obligation is to provide fiber splicing services as required based on short-term work orders as work is assigned by the Customer. The Company is required to complete the description of work described in the work order and test the service provided prior to any recognition of revenue and invoicing. The short-term work orders are for very specific performance obligations which are performed from start to finish within two weeks or less, and more often, within one week. The Company is required to adhere to the rules and regulations that are outlined in the Agreement between the Company and the Customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost for the work performed is outlined in the individual work orders based on the detailed description of work to be performed. All of the revenue is recognized immediately upon completion of the work in each work order. A 5% retainage will be withheld by the Customer upon payment of invoices and will be paid to the Company within one year after termination of the contract. The retainage can be utilized by Customer for any claims that may arise after work is completed up through one year after completion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue recognized during the three months ended March 31, 2023 was generated by the Company’s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was immaterial. No revenue was recognized by the Company during the three months ended March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	115879562	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20322287	shares
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	650000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Number Of Employees DefinedContributionPlanNumberOfEmployees	12	pure
CY2023Q1	crkn	Asset Acquisition Term AssetAcquisitionTerm	P1Y
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	656000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	200000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	5000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	529000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	338000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	7000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	652000	usd
CY2023Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	645000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2528000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	500000	usd
CY2023Q1	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	200000	usd
CY2023Q1	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	256000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	300000	usd
CY2023Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	120000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	99000	usd
CY2023Q1	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	66000	usd
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	142000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	97000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	63000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	723000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3118000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1871000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	590000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	128000000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	54000000	usd
CY2023Q1	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2023Q1	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2023Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	200000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-631000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-577000	usd
CY2023Q1	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1744000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1598000	usd
CY2023Q1	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	200000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	177000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	235000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	234000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	197000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	901000	usd
CY2023Q1	crkn	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1744000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	53000000	usd
CY2023Q1	crkn	Standing Letterof Credit StandingLetterofCredit	223000	usd
CY2022	crkn	Standing Letterof Credit StandingLetterofCredit	223000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	9943000	usd
CY2023Q1	crkn	Deferreddebtissuancecoststotal deferreddebtissuancecoststotal	10166000	usd
CY2022	crkn	Deferreddebtissuancecoststotal deferreddebtissuancecoststotal	223000	usd
CY2023Q1	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	1905000	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	73000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8261000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	150000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9900000	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1600000	usd
CY2023Q1	crkn	Convertible Promissory Notes ConvertiblePromissoryNotes	2000000	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3191000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2332000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1654000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	5500000	usd
CY2023Q1	crkn	Shares Of Common Stock SharesOfCommonStock	1887919	shares
CY2023Q1	crkn	Fair Value Converted Notes FairValueConvertedNotes	500000	usd
CY2023Q1	crkn	Change In Fair Value ChangeInFairValue	400000	usd
CY2023Q1	crkn	Agreement Issued AgreementIssued	2000000	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	2500000	shares
CY2023Q1	crkn	Fair Value Amount FairValueAmount	1100000	usd
CY2023Q1	crkn	Warrants Exercised WarrantsExercised	6405844	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.487	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0398	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0474	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y9M18D
CY2023Q1	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	155000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	510000	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	25000	usd
CY2023Q1	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	15000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	104000	usd
CY2023Q1	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	35000	usd
CY2022Q4	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	7000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	230000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	621000	usd
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	5400000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	21749402	shares
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.54	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.35	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.49
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.32
CY2023Q1	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2023Q1	us-gaap	Restricted Investments Percent Of Net Assets RestrictedInvestmentsPercentOfNetAssets	0.05	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2023Q1	us-gaap	Shares Issued SharesIssued	1903429	shares
CY2023Q1	crkn	Converted Minimum Price Per Share ConvertedMinimumPricePerShare	0.157
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	150000	usd
CY2023Q1	crkn	Common Stock Of Insurance Shares CommonStockOfInsuranceShares	1887919	shares
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	2000000	usd
CY2023Q1	crkn	Issuance Date IssuanceDate	P60D
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	2000000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.5
CY2023Q1	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	3200000	usd
CY2023Q1	us-gaap	Senior Notes SeniorNotes	1200000	usd
CY2023Q1	crkn	Purchase Of Warrants PurchaseOfWarrants	2500000	shares
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1000000	usd
CY2023Q1	crkn	Warrant Exercise Price WarrantExercisePrice	0.322
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	crkn	Common Stock Shares Outstanding Percentage CommonStockSharesOutstandingPercentage	0.1999	pure
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2900000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	4350000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	1800000	shares
CY2023Q1	crkn	Common Stock With Fair Value CommonStockWithFairValue	600000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	500000	shares
CY2023Q1	crkn	Underwriters Purchase UnderwritersPurchase	62500	shares
CY2023Q1	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.8
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4200000	shares
CY2023Q1	crkn	Total Number Of Outstanding Shares Percentage TotalNumberOfOutstandingSharesPercentage	0.199	pure
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	19000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	248000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	209000	usd
CY2023Q1	crkn	Other Research And Development Expenses OtherResearchAndDevelopmentExpenses	59000	usd
CY2022	crkn	Other Research And Development Expenses OtherResearchAndDevelopmentExpenses	55000	usd
CY2023Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	122000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1028000	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	181000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1083000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9513624	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	26188000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	90138	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.29
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9423486	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8521662	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.8
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	628780	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	130867	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.55
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	497913	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.32
CY2022	crkn	Warrants Issued Purchase Share WarrantsIssuedPurchaseShare	21759402	shares
CY2022	crkn	Warrant Exercise Price WarrantExercisePrice	0.32
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	6405844	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6405844
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.32
CY2023Q1	crkn	Warrants To Purchase Shares warrantsToPurchaseShares	5813414	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.32
CY2022Q3	us-gaap	Retail Land Sales Installment Method Sales Value RetailLandSalesInstallmentMethodSalesValue	85450000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 300,000 shares of the Company’s common stock at $0.75 per share. The warrant has a five-year life and expires on August 12, 2027.
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	161700000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	161700000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	85450000	usd
CY2023Q1	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	223000000	usd
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	usd
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	usd
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4500000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7550000	usd
CY2022Q1	crkn	Eighth Amendmen Description EighthAmendmenDescription	the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11.
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	44252000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	41323000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	7388000	usd
CY2021Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.03	pure
CY2021Q2	us-gaap	Deposit Assets DepositAssets	8315000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1800000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	58000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	192000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	153000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2336000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	584000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	678000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	475000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	390000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	58000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2185000	usd
CY2023Q1	crkn	Operating Leases Future Minimum Payments Present Value Discount OperatingLeasesFutureMinimumPaymentsPresentValueDiscount	379000	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1806000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2022Q1	us-gaap	Revenues Revenues		usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022Q1	us-gaap	Gross Profit GrossProfit		usd
CY2022Q1	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2022Q1	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1		usd
CY2023Q1	us-gaap	Other Income OtherIncome		usd
CY2022Q1	us-gaap	Other Income OtherIncome		usd
CY2022Q1	us-gaap	Other Expenses OtherExpenses		usd
CY2022Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments		usd
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15856316	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29695083	shares
CY2023Q1	crkn	Deemed Dividend For Repricing Of Series D Preferred Stock DeemedDividendForRepricingOfSeriesDPreferredStock		usd
CY2022Q1	crkn	Delivery Of Restricted Common Stock Value DeliveryOfRestrictedCommonStockValue		usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability		usd
CY2022Q1	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes		usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2022Q1	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022Q1	us-gaap	Other Expenses OtherExpenses		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	crkn	Issuance Of Series E Preferred Stock In Connection With Loc IssuanceOfSeriesEPreferredStockInConnectionWithLOC		usd
CY2022Q1	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes		usd
CY2023Q1	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable		usd
CY2022Q1	crkn	Commitment To Issue Shares Of Common Stock In Connection With March Waiver Agreement CommitmentToIssueSharesOfCommonStockInConnectionWithMarchWaiverAgreement		usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2022	us-gaap	Professional Fees ProfessionalFees		usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross		usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit		usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent		usd
CY2023Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001761696

Files In Submission

Name	View Source	Status
0001213900-23-042072-index-headers.html	Edgar Link	pending
0001213900-23-042072-index.html	Edgar Link	pending
0001213900-23-042072.txt	Edgar Link	pending
0001213900-23-042072-xbrl.zip	Edgar Link	pending
crkn-20230331.xsd	Edgar Link	pending
f10q0323ex31-1_crownelectro.htm	Edgar Link	pending
f10q0323ex31-2_crownelectro.htm	Edgar Link	pending
f10q0323ex32-1_crownelectro.htm	Edgar Link	pending
f10q0323ex32-2_crownelectro.htm	Edgar Link	pending
f10q0323_crownelectro.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
crkn-20230331_def.xml	Edgar Link	unprocessable
crkn-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crkn-20230331_lab.xml	Edgar Link	unprocessable
f10q0323_crownelectro_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crkn-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2023 Q2 Form 10-Q Financial Statement

#000121390023042072 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2023 Q2 Form 10-Q Financial Statement

#000121390023042072 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn